Journal ArticleDOI
Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment
Su Chu,Helen Xu,Helen Xu,Neil P. Shah,Neil P. Shah,David S. Snyder,David S. Snyder,Stephen J. Forman,Stephen J. Forman,Charles L. Sawyers,Charles L. Sawyers,Ravi Bhatia,Ravi Bhatia +12 more
TLDR
It is concluded that BCR-ABL kinase mutations can be detected in CD34+ cells from CML patients in CCR on imatinib, may contribute to persistence of small populations of malignant progenitors, and could be a potential source of relapse.About:
This article is published in Blood.The article was published on 2005-03-01. It has received 226 citations till now. The article focuses on the topics: Imatinib mesylate & Imatinib.read more
Citations
More filters
Journal ArticleDOI
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more
TL;DR: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
Journal ArticleDOI
Targeting cancer with small molecule kinase inhibitors
TL;DR: This Review provides a broad overview of some of the approaches currently used to discover and characterize new kinase inhibitors, and discusses the current challenges in the field.
Journal ArticleDOI
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Michele Baccarani,Giuseppe Saglio,John M. Goldman,Andreas Hochhaus,Bengt Simonsson,Frederick R. Appelbaum,Jane F. Apperley,Francisco Cervantes,Jorge E. Cortes,Michael W. Deininger,Alois Gratwohl,François Guilhot,Mary M. Horowitz,Timothy P. Hughes,Hagop M. Kantarjian,Richard A. Larson,Dietger Niederwieser,Richard T. Silver,Rüdiger Hehlmann +18 more
Journal ArticleDOI
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy P. Hughes,Michael W. Deininger,Andreas Hochhaus,Susan Branford,Jerald P. Radich,Jaspal Kaeda,Michele Baccarani,Jorge E. Cortes,Nicholas C.P. Cross,Brian J. Druker,Jean Gabert,David Grimwade,Rüdiger Hehlmann,Suzanne Kamel-Reid,Jeffrey H. Lipton,Janina A. Longtine,Giovanni Martinelli,Giuseppe Saglio,Simona Soverini,Wendy Stock,John M. Goldman +20 more
TL;DR: Suggestions are made for harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR -ABL transcript levels on an internationally agreed scale.
Journal ArticleDOI
Targeted cancer therapy
TL;DR: In this paper, the authors proposed to target malfunctioning molecules and pathways to achieve more effective and rational cancer therapy, which can be seen as a promising approach for targeting malfunctioning proteins and pathways.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining.
TL;DR: An unsuspected abnormality in all cells from the nine patients with chronic myelogenous leukaemia has been detected with quinacrine fluorescence and various Giemsa staining techniques, suggesting that there may be a hitherto undetected translocation between the long arm of 22 and thelong arm of 9, producing the 9q+ chromosome.
Journal ArticleDOI
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Brian J. Druker,Shu Tamura,Elisabeth Buchdunger,Sayuri Ohno,Gerald M. Segal,Shane Fanning,Jürg Zimmermann,Nicholas B. Lydon +7 more
TL;DR: A compound, designed to inhibit the Abl protein tyrosine kinase, was evaluated for its effects on cells containing the Bcr–Abl fusion protein and it was found that this compound may be useful in the treatment of bcr–abl–positive leukemias.
Journal ArticleDOI
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more
TL;DR: Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Related Papers (5)
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker,François Guilhot,Stephen G. O'Brien,Insa Gathmann,Hagop M. Kantarjian,Norbert Gattermann,Michael W. Deininger,Richard T. Silver,John M. Goldman,Richard Stone,Francisco Cervantes,Andreas Hochhaus,Bayard L. Powell,Janice Gabrilove,Philippe Rousselot,Josy Reiffers,Jan J. Cornelissen,Timothy P. Hughes,Hermine Agis,Thea Kolsen Fischer,Gregor Verhoef,John D. Shepherd,Giuseppe Saglio,Alois Gratwohl,Johan Lanng Nielsen,Jerald P. Radich,Bengt Simonsson,Kerry Taylor,Michele Baccarani,Charlene So,Laurie Letvak,Richard A. Larson +31 more